Beta Bionics, Inc. (NASDAQ:BBNX) Given Consensus Rating of “Moderate Buy” by Brokerages

Shares of Beta Bionics, Inc. (NASDAQ:BBNX) have received an average rating of “Moderate Buy” from the thirteen ratings firms that are covering the stock, MarketBeat Ratings reports. One investment analyst has rated the stock with a sell recommendation, three have assigned a hold recommendation, eight have assigned a buy recommendation and one has issued a strong buy recommendation on the company. The average 1-year target price among analysts that have issued a report on the stock in the last year is $29.3333.

Several research firms have recently commented on BBNX. Wall Street Zen upgraded shares of Beta Bionics from a “strong sell” rating to a “hold” rating in a research note on Saturday, November 1st. The Goldman Sachs Group upped their target price on Beta Bionics from $26.00 to $33.00 and gave the company a “buy” rating in a research report on Wednesday, October 29th. Lake Street Capital reaffirmed a “buy” rating and set a $35.00 price target on shares of Beta Bionics in a research report on Wednesday, October 29th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Beta Bionics in a research note on Monday, December 22nd. Finally, Piper Sandler restated an “overweight” rating and issued a $32.00 price objective (up from $26.00) on shares of Beta Bionics in a research note on Wednesday, October 29th.

Insider Buying and Selling at Beta Bionics

In other Beta Bionics news, CFO Stephen Feider sold 15,018 shares of Beta Bionics stock in a transaction that occurred on Wednesday, October 1st. The shares were sold at an average price of $20.76, for a total transaction of $311,773.68. Following the completion of the sale, the chief financial officer directly owned 44,041 shares in the company, valued at approximately $914,291.16. The trade was a 25.43% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, Director Maria Palasis sold 1,406 shares of the stock in a transaction on Friday, October 31st. The stock was sold at an average price of $26.91, for a total transaction of $37,835.46. Following the completion of the sale, the director owned 9,841 shares in the company, valued at $264,821.31. The trade was a 12.50% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last quarter, insiders sold 25,302 shares of company stock valued at $568,505.

Hedge Funds Weigh In On Beta Bionics

A number of institutional investors have recently modified their holdings of BBNX. GPS Wealth Strategies Group LLC boosted its stake in shares of Beta Bionics by 45.0% in the third quarter. GPS Wealth Strategies Group LLC now owns 1,450 shares of the company’s stock worth $29,000 after buying an additional 450 shares during the last quarter. EverSource Wealth Advisors LLC lifted its holdings in Beta Bionics by 203.6% in the third quarter. EverSource Wealth Advisors LLC now owns 2,377 shares of the company’s stock valued at $47,000 after acquiring an additional 1,594 shares during the period. Strs Ohio acquired a new position in Beta Bionics in the first quarter valued at approximately $29,000. Ameritas Investment Partners Inc. boosted its position in Beta Bionics by 139.1% in the 3rd quarter. Ameritas Investment Partners Inc. now owns 3,202 shares of the company’s stock worth $64,000 after purchasing an additional 1,863 shares in the last quarter. Finally, Legal & General Group Plc grew its stake in shares of Beta Bionics by 197.4% during the 2nd quarter. Legal & General Group Plc now owns 3,976 shares of the company’s stock worth $58,000 after purchasing an additional 2,639 shares during the period.

Beta Bionics Stock Performance

Shares of BBNX stock opened at $31.86 on Friday. Beta Bionics has a fifty-two week low of $8.89 and a fifty-two week high of $32.71. The firm has a market capitalization of $1.40 billion and a price-to-earnings ratio of -7.29. The stock’s 50-day simple moving average is $27.97 and its 200-day simple moving average is $21.50.

Beta Bionics (NASDAQ:BBNX) last announced its quarterly earnings data on Tuesday, October 28th. The company reported ($0.33) EPS for the quarter, beating the consensus estimate of ($0.45) by $0.12. The firm had revenue of $27.25 million during the quarter, compared to analyst estimates of $23.92 million. Beta Bionics had a negative net margin of 87.89% and a negative return on equity of 35.72%.

Beta Bionics Company Profile

Beta Bionics, a clinical-stage medical device company headquartered in Boston, Massachusetts, is focused on revolutionizing the management of type 1 diabetes through automated insulin delivery solutions. The company’s flagship product, the iLet Bionic Pancreas system, is designed to simplify glycemic control by automatically adjusting insulin dosing in response to continuous glucose monitoring data. By integrating advanced algorithmic control with wearable infusion pumps, the iLet aims to reduce the daily burden of diabetes management and improve clinical outcomes for patients.

At the core of Beta Bionics’ offering is its proprietary bionic pancreas software, which can operate in both insulin-only and dual‐hormone modes.